ABAngela Brooks-Wilson

Angela Brooks-Wilson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angela Brooks-Wilson has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DNA methylation variability provides a complementary epigenetic signature of aging heterogeneity: findings from the Canadian Longitudinal Study on Aging and the Baltimore Longitudinal Study of Aging

    by Olga Vishnyakova, Joosung Min, Ann Z Moore, Toshiko Tanaka, Luigi Ferrucci, Xiaowei Song, Kenneth Rockwood, Angela Brooks-Wilson, Lloyd T Elliott

    Background: Human aging does not follow a single trajectory. Epigenetic changes offer insight into the heterogeneity in aging by reflecting the combined influence of genetic, environmental, and lifestyle factors on the timing and progression of age-related changes beyond what chronological age alone can explain. Recent studies in cancer and aging underscore the importance of methylation variability as a marker of biological dysregulation. Methods: We investigated the role of DNA methylation in aging heterogeneity by performing epigenome-wide differential methylation and variance association analyses in blood samples from 1445 Canadians aged 45 to 85 from the Canadian Longitudinal Study on Aging. Results: We identified 448 differentially methylated regions and 488 differentially variable regions associated with health decline as measured by the health deficit accumulation frailty index, cognitive function, and physical function. These two classes of regions showed minimal overlap, with distinct gene coverage, suggesting that variability contributes a complementary signal to aging heterogeneity. Genes overlapped by differentially methylated regions were enriched for immune and inflammation-related pathways, whereas differentially variable regions highlighted additional localized, CpG‑island-enriched signals shared across health domains, consistent with regionally structured rather than diffuse dysregulation. By integrating significant CpGs from both analyses, we constructed an epigenetic biomarker. The biomarker was associated with all-cause mortality and showed higher discrimination than biomarkers constructed from differential methylation or variability alone, with a similar pattern reproduced in the Baltimore Longitudinal Study of Aging. Conclusions: These findings suggest that DNA methylation variability may provide a complementary dimension of epigenetic aging and support further evaluation in larger cohorts with more mortality events.

  • Open Access

    Genome-wide association study and pathway analysis of healthy aging in Super Seniors

    by Rawnak Hoque, Stephen Leach, Angela Brooks-Wilson

    Healthy aging is a complex process influenced by genetic, environmental, and lifestyle factors. Although prior genetic studies have identified loci associated with longevity, replication has often been limited by strong non-genetic influences. To investigate the genetic contributors to healthy aging, we performed a genome-wide association study (GWAS) and pathway analyses in 597 Super Seniors-individuals aged ≥ 85 years with no history of cancer, cardiovascular disease, diabetes, dementia, or major pulmonary disease-compared to 420 mid-life population-based controls that represent the population before selection for survival from age-related disorders. Candidate variant analyses confirmed known associations at the APOE locus, where APOE4 carriers had reduced odds of healthy aging (P = 0.0025), with stronger effects in females (P = 8.82 × 10⁻4). Several FOXO3 variants (rs10457180, rs13217795, rs2802292) showed nominal associations with increased odds of being a Super Senior, again primarily among females. The GWAS, conducted on 8 million imputed variants, identified no genome-wide significant variants; however, suggestive associations were observed at the EMG1/LPCAT3/C1S, AHI1, OR10P1, TRPC4, NR3C2, and IGFBP7 loci. The most significant locus, EMG1/LPCAT3/C1S, has been linked to red blood cell fatty acid levels, lipid homeostasis, atherosclerosis, and insulin resistance-processes relevant to healthy aging. Candidate pathway analyses identified significant enrichment after FDR correction in six key aging-related signaling pathways: PI3K-AKT (FDR = 0.0016), cellular senescence (FDR = 0.011), insulin (FDR = 0.012), autophagy (FDR = 0.017), p53 (FDR = 0.017), and mTOR (FDR = 0.027). Genome-wide pathway analysis further highlighted both known and novel genetic pathways influencing healthy aging.

  • Open Access

    A New Sparse Bayesian Quantile Neural Network-based Approach and Its Application to Discover Physiological Sweet Spots in the Canadian Longitudinal Study on Aging

    by Joosung Min, Olga Vishnyakova, Angela Brooks-Wilson, Lloyd T. Elliott

    Identifying physiological sweet spots (optimal ranges for homeostasis) is essential for precision medicine. However, traditional statistical methods often rely on globally linear or locally jagged models that struggle to capture the smooth, non-linear nature of biological regulation in high-dimensional data. We present the Quantile Feature Selection Network (Q-FSNet), a neural network-based framework that integrates quantile regression, feature selection, and uncertainty estimation to identify biomarkers with sweet spots. Unlike traditional methods, Q-FSNet learns continuous response curves without requiring pre-specified number of change points. We further introduce Quantile Dirichlet Network (Q-DirichNet), a fully Bayesian extension that utilizes Dirichlet priors to automate feature shrinkage. Using data from the Canadian Longitudinal Study on Aging, we identified 25 metabolites with distinct homeostatic ranges for which biological age acceleration is minimized. The metabolites with sweet spots for biological aging include some derived from diet or produced by the gut microbiome; this highlights their potential for knowledge translation and public health impact. Our results, corroborated by existing literature, demonstrate that these sparse neural network-based methods offer a scalable and interpretable tool for discovering metabolic signatures of healthy aging vs. dysregulation in large-scale omics research.

  • Open Access

    Metabolomic sweet spot clock predicts mortality and age-related diseases in the Canadian Longitudinal Study on Aging

    by Olga Vishnyakova, Joosung Min, Stephen Leach, Xiaowei Song, Kenneth Rockwood, Angela Brooks-Wilson, Lloyd T. Elliott

    Background Chronological age does not capture individual health or resilience. Advances in metabolomics have enabled development of molecular aging biomarkers that capture deviations between biological and chronological age, highlighting how genetics, environment, and lifestyle shape biological aging. Despite their promise, metabolomic biomarkers face challenges such as interpretability, non-linearity, and reproducibility. Methods We have developed a metabolomic predictor of biological age based on untargeted metabolomic profiling of individuals aged 45–85 years from the Canadian Longitudinal Study on Aging. To enhance interpretability, we first identified metabolites related to health based on variance heterogeneity. For metabolites with identifiable optimal levels, or “sweet spots”, we modeled non-linearity using deviations from these values. A penalized regression model was trained on the Frailty Index using sweet spot deviations as predictors. Results Here we show that the Sweet Spot Clock built on 178 health-related metabolites is strongly associated with all-cause mortality (HR = 1.08, p = 5.8×10−12, C-index=0.841) and age-related diseases. The biomarker outperforms models trained on chronological age and those using raw metabolite levels, underscoring the importance of modeling non-linearity. It remains predictive after adjusting for age, sex, lifestyle and socioeconomic factors, though its added value over standard health and demographic measures is modest. The model generalizes to an independent cohort of individuals aged 85 years and older. Conclusions The Sweet Spot Clock provides a reproducible and interpretable measure of biological age. By modeling deviations from optimal metabolite levels and training on health status rather than age, it offers a tool for understanding aging heterogeneity and identifying individuals at risk of health decline.


  • Open Access

    Supplementary Data from B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

    by Sophia S. Wang, Claire M. Vajdic, Martha S. Linet, Susan L. Slager, Jenna Voutsinas, Alexandra Nieters, Delphine Casabonne, James R. Cerhan, Wendy Cozen, Graciela Alarcón, et al.

    Supplementary Data from B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

  • Open Access

    Metabolites mediate genetic effects on disease in the Canadian Longitudinal Study on Aging

    by Joosung Min, Olga Vishnyakova, Angela Brooks-Wilson, Lloyd T. Elliott

    Understanding the biological mechanisms linking genetic variants to disease risk is essential for advancing precision health. We have developed a causal mediation analysis framework, the C-MAPLE (Causal Mediation Analysis of Pathways Linking Exposures) method, to identify disease-causing pathways for which the effect of genetic variants is mediated through metabolites to impact age-related diseases. Unlike Mendelian randomization, our approach is robust to horizontal pleiotropy, and models multiple mediators and interactions between genetic variants and metabolites simultaneously. To ensure robust model selection, we incorporate least absolute shrinkage and selection operator (LASSO) with stability selection, which can effectively select relevant mediators even in the presence of unmeasured confounding. We also introduce a dynamic adjustment to the number of bootstrap trials to reduce computational burden during uncertainty estimation. Applying this novel framework to the Canadian Longitudinal Study on Aging, we identified 190 potential causal links involving 108 genetic variants, 176 metabolites, and 6 age-related diseases. Our method and findings highlight the utility of causal mediation analysis in uncovering metabolite-mediated genetic mechanisms. This method, combined with large-scale population data sets, has the potential to revolutionize the identification of targets for downstream clinical research, and the development of personalized disease prevention, interventions, and therapeutics.

  • Open Access

    Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses

    by Amy Moore, Eleanor Kane, Lauren R. Teras, Mitchell J. Machiela, Joshua Arias, Orestis A. Panagiotou, Alain Monnereau, Nicole Wong Doo, Zhaoming Wang, Susan L. Slager, et al.

    Obesity has been associated with non‐Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome‐wide association studies of European ancestry ( N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist‐to‐hip ratio (WHR), and waist‐to‐hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.18, 95% confidence interval (95% CI): 1.05–1.33, p = .005]. This finding was consistent with Mendelian randomization analyses, which demonstrated a similar increased risk of DLBCL with higher genetically determined BMI (OR per SD = 1.12, 95% CI: 1.02–1.23, p = .03). No significant associations were observed with other NHL subtypes. Our study demonstrates a positive link between a genetically determined BMI and an increased risk of DLBCL, providing additional support for increased adiposity as a risk factor for DLBCL.


  • Open Access

    Epigenetic signature of heterogeneity in aging: Findings from the Canadian Longitudinal Study on Aging

    by Olga Vishnyakova, Joosung Min, Ann Z. Moore, Toshiko Tanaka, Luigi Ferrucci, Xiaowei Song, Kenneth Rockwood, Angela Brooks-Wilson, Lloyd T. Elliott

    Human aging does not follow a single trajectory. Epigenetic changes offer insight into the heterogeneity in aging by reflecting the combined influence of genetic, environmental, and lifestyle factors on the timing and progression of age-related changes beyond what chronological age alone can explain. Emerging research in cancer and aging highlights the importance of methylation variability as a marker of biological disruption. It also shows that there is little overlap between CpGs differing in means versus variability. We investigated the role of DNA methylation in aging heterogeneity by performing epigenome-wide differential methylation and variance association analysis in blood samples from 1,445 Canadians aged 45 to 85. We identified 448 differentially methylated regions (DMRs) and 488 differentially variable regions (DVRs) associated with health decline as measured by health deficit accumulation (i.e. the Frailty Index), cognitive, and physical function. We observed minimal overlap between these types of regions, with distinct genes, highlighting a unique and potentially additional contribution of variability to age-related epigenetic changes. Gene ontology analyses of DMRs revealed enrichment in immune and inflammation-related pathways pointing to immune function as a key driver of aging heterogeneity. By integrating significant regions from both analyses, we constructed a composite epigenetic biomarker. Our biomarker outperformed control models built on differential methylation alone as well as established epigenetic biomarkers (e.g. GrimAge, PhenoAge) in predicting mortality and the onset of chronic obstructive pulmonary disease.

  • Open Access

    Figure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

    by Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer, Nicola S. Meagher, Sian Fereday, Laura Twomey, Kathleen I. Pishas, et al.

    Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples (27) are shown, as well as alterations in immune genes and CCNE1. Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS < 2 years), tumor CHORD (41) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status (BRCA1-type HRD; BRCA2-type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).

  • Open Access

    Supplementary Table S12 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

    by Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer, Nicola S. Meagher, Sian Fereday, Laura Twomey, Kathleen I. Pishas, et al.

    Supplementary Table S12. Clinical characteristics of patients with HGSC.